Legend Biotech to Host Investor Conference Call on Second Quarter 2025 Results
Legend Biotech (NASDAQ: LEGN), a global cell therapy leader, has scheduled an investor conference call for Monday, August 11, 2025, at 8:00 am ET to discuss their second quarter 2025 financial results. The company's senior leadership will present the quarterly performance overview during the call.
Investors can access the live audio webcast through a provided weblink. Following the call, both the webcast replay and earnings release will be accessible on Legend Biotech's website in the Investor Relations section under Events and Presentations, approximately two hours after the call's conclusion.
Legend Biotech (NASDAQ: LEGN), leader globale nella terapia cellulare, ha programmato una conference call per gli investitori per lunedì 11 agosto 2025, alle 8:00 ET per discutere i risultati finanziari del secondo trimestre 2025. Il team dirigenziale dell'azienda presenterà una panoramica delle performance trimestrali durante la chiamata.
Gli investitori potranno seguire la diretta audio tramite un link fornito. Dopo la chiamata, sia la registrazione della webcast che il comunicato sugli utili saranno disponibili sul sito web di Legend Biotech, nella sezione Investor Relations sotto Eventi e Presentazioni, circa due ore dopo la conclusione della chiamata.
Legend Biotech (NASDAQ: LEGN), líder global en terapia celular, ha programado una llamada de conferencia para inversores el lunes 11 de agosto de 2025 a las 8:00 am ET para discutir los resultados financieros del segundo trimestre de 2025. La alta dirección de la compañía presentará una visión general del desempeño trimestral durante la llamada.
Los inversores podrán acceder a la transmisión de audio en vivo a través de un enlace proporcionado. Después de la llamada, tanto la repetición de la transmisión como el comunicado de resultados estarán disponibles en el sitio web de Legend Biotech, en la sección de Relaciones con Inversores, bajo Eventos y Presentaciones, aproximadamente dos horas después de que finalice la llamada.
Legend Biotech (NASDAQ: LEGN)는 글로벌 세포 치료 선도 기업으로서 2025년 8월 11일 월요일 오전 8시(동부시간)에 2025년 2분기 재무 실적을 논의하기 위한 투자자 컨퍼런스 콜을 예정하였습니다. 회사의 고위 경영진이 콜에서 분기 실적 개요를 발표할 예정입니다.
투자자들은 제공된 링크를 통해 실시간 오디오 웹캐스트에 접속할 수 있습니다. 콜 종료 약 2시간 후에는 웹캐스트 재방송과 실적 발표 자료가 Legend Biotech의 웹사이트 투자자 관계 섹션 내 이벤트 및 프레젠테이션에서 확인 가능합니다.
Legend Biotech (NASDAQ : LEGN), un leader mondial de la thérapie cellulaire, a programmé une conférence téléphonique pour les investisseurs le lundi 11 août 2025 à 8h00 ET afin de discuter des résultats financiers du deuxième trimestre 2025. La haute direction de l'entreprise présentera un aperçu des performances trimestrielles lors de cet appel.
Les investisseurs pourront accéder à la diffusion audio en direct via un lien fourni. Après l'appel, la rediffusion du webcast ainsi que le communiqué des résultats seront disponibles sur le site web de Legend Biotech, dans la section Relations Investisseurs sous Événements et Présentations, environ deux heures après la fin de l'appel.
Legend Biotech (NASDAQ: LEGN), ein weltweit führendes Unternehmen im Bereich Zelltherapie, hat eine Telefonkonferenz für Investoren für Montag, den 11. August 2025, um 8:00 Uhr ET angesetzt, um die Finanzergebnisse des zweiten Quartals 2025 zu besprechen. Die Geschäftsleitung des Unternehmens wird während des Calls einen Überblick über die Quartalsleistung geben.
Investoren können über einen bereitgestellten Link auf das Live-Audio-Webcast zugreifen. Nach dem Call sind sowohl die Aufzeichnung des Webcasts als auch die Gewinnmitteilung auf der Website von Legend Biotech im Bereich Investor Relations unter Veranstaltungen und Präsentationen etwa zwei Stunden nach Ende des Calls verfügbar.
- None.
- None.
SOMERSET, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, August 11, 2025, to review second-quarter 2025 results.
During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s performance for the quarter.
Investors and other interested parties may join the live audio webcast of the call via this weblink.
A replay of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech’s website under the Events and Presentations section approximately two hours after the call concludes.
ABOUT LEGEND BIOTECH
With over 2,600 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.
Learn more at www.legendbiotech.com, and follow us on X (formerly Twitter) and LinkedIn.
INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com
PRESS CONTACT:
Mary Ann Ondish
Tel: (914) 552-4625
media@legendbiotech.com
FAQ
When is Legend Biotech's Q2 2025 earnings call?
How can investors access Legend Biotech's Q2 2025 earnings call?
When will Legend Biotech's Q2 2025 earnings materials be available?
Who will present during Legend Biotech's Q2 2025 earnings call?
